MDB Capital (MDBH) Q2 2026 earnings review
Asset Sales Become Existential as Microcap Winter Freezes Core Business
MDB Capital is hitting the brakes on its core "Public Venture" model. Facing a hostile microcap environment and an accelerating cash burn ($5.5M used in H1 2026), management is abandoning its ambitious goal of 3-5 IPOs per year to focus entirely on survival and asset monetization. The new strategy relies on selling its clearing platform (Public Ventures) and spinning out its IP law firm (PatentVest) to chop operating expenses from an $11M+ run rate down to $6M. While fee income ticked up to $1.0M in Q2, a concerning 59% of it came from related-party eXoZymes. With just $9.9M in total cash remaining and a devastating post-quarter $11.3M hit to its eXoZymes equity value, MDBH is in a race against the clock to execute these spin-outs before its runway evaporates.
🐂 Bull Case
Stripping out PatentVest and Public Ventures could drop fixed costs to ~$6M per year. If executed, this extends the company's runway significantly without requiring dilutive capital raises.
The Paulex Bio IPO (slated for late 2026) and a potential HeartBeam partnership could provide sudden liquidity and valuation spikes, proving the model still works for carefully curated assets.
🐻 Bear Case
eXoZymes, their primary success story, suffered a brutal post-quarter price drop to $5.76, wiping out $11.3M in unrecorded value. The 'billion-dollar potential' narrative is currently detached from market reality.
Over 50% of Q2's fee income ($592k) was extracted from eXoZymes. Pumping up top-line revenue using cash from their own struggling portfolio companies is an unsustainable loop.
⚖️ Verdict: 🔴
Bearish. The pivot to expense reduction is absolutely necessary, but the rapidly depreciating investment portfolio and heavy reliance on related-party fees are massive red flags. Execution risk on the platform sales is currently at maximum levels.
Key Themes
eXoZymes Subsequent Impairment Destroys Value
Reversing. Management spent the earnings call touting eXoZymes' manufacturing scale-up, but the 10-Q tells a much darker story. Note 14 reveals the stock collapsed to $5.76 in August. This triggered an unrecorded $11.3M loss on top of the $641k impairment already taken in Q2. MDB's carrying value of this crucial asset is plummeting faster than they can monetize it.
MDB Direct & PatentVest Spinoffs
Accelerating. The primary catalyst for the stock is now entirely offloading internal assets. MDB Direct (Public Ventures) is reportedly fielding LOIs from 4-5 parties. This transaction is the linchpin to slashing the $11M+ annual operating expenses to a sustainable $6M target. Management views these assets as fully developed and ready to be funded by external strategic partners.
The Core 'Scale-Up' Model is Officially Stalled
Decelerating. In 2025, the narrative was scaling up to 3-5 company launches per year. In Q2 2026, the CEO admitted the sub-$200M microcap space is 'evacuated' and the macro backdrop is hostile. MDB completed only two transactions in H1 2026 and is reverting to a defensive 'rifle-shot' approach, effectively shelving its primary growth narrative.
AI Integration in Legal Tech
Stable. PatentVest is pivoting to an AI-native Alternative Business Structure (ABS) law firm in Arizona. Management claims their proprietary AI agents have slashed patentability analysis time from 45 hours down to 1.5 hours. They intend to finance this entity independently and take it public by 2027 to attack the $10B-$15B patent prosecution market.
Other KPIs
Down sharply from $15.54 million at year-end 2025. With H1 2026 operating cash burn hitting $5.5 million, the company essentially has less than 12 months of runway remaining if asset sales fail to materialize or if related-party fee income dries up.
While this looks like a stark improvement from $0 in Q2 2025, a critical look shows that $592,000 (59%) of this came directly from related-party eXoZymes. True external revenue generation remains anemic.
Widened from an $(8.25) million loss a year ago. The damage was driven almost entirely by a $1.94M equity method loss and $1.83M in unrealized securities losses. Operating expenses were virtually flat YoY at $5.57M, highlighting the urgent need for the promised spinoffs.
Guidance
Decelerating. Management intends to cut current run-rate expenses (currently tracking at ~$11M+ annually) nearly in half by unloading the MDB Direct platform and spinning off PatentVest. This is the most critical forward-looking metric for the company's survival.
Stable. The company is projecting two transactions for the second half of the year (including Paulex Bio). This confirms the retreat from their prior 3-5 launch volume target, returning to a highly selective capital deployment strategy.
Key Questions
Liquidity Contingency
If the sale or partnership of MDB Direct (Public Ventures) is delayed past Q3, will you be forced into a highly dilutive capital raise before year-end given the current burn rate?
eXoZymes Capital Requirements
With eXoZymes' stock dropping to $5.76 post-quarter, how does this impact their ability to raise non-dilutive capital, and will MDB have to participate financially to support them despite your own cash constraints?
Quality of Revenue
Over half of Q2 fee income was extracted from your own portfolio company. How much purely external fee income is currently contracted and expected to close in H2 2026?